Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040792 | 0.91 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL13456266 | 0.84 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL3043420 | 0.83 | CNR2 (0.86) | CNR2CNR1 | |
| SCHEMBL3044068 | 0.82 | CNR2 (0.69) | CNR2CNR1 | |
| SCHEMBL3022066 | 0.82 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL3022960 | 0.81 | MCHR1 (0.68) | CNR2CNR1 | |
| SCHEMBL3044630 | 0.81 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3017636 | 0.80 | GLA (0.55) | CNR2CNR1 | |
| SCHEMBL2372639 | 0.79 | CNR2 (0.48) | CNR2CNR1 | |
| SCHEMBL3034459 | 0.79 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | disclosed |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | WYETH LLC (US) | 2010-08-12 | — | — | US | disclosed |
| US-7723332-B2 | Aryl sulfonamides useful for modulation of the progesterone receptor | WYETH LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | disclosed |
| EP-2139852-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | Pharmos Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2137145-A2 | CYANOPYRROL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | Wyeth (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090312414-A1 | Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists | THE PROCTER & GAMBLE COMPANY (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090312414-A1 | Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists | THE PROCTER & GAMBLE COMPANY (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009140078-A1 | TREATMENT OF LOWER URINARY TRACT DYSFUNCTION WITH CB2-RECEPTOR-SELECTIVE AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2008109055-A2 | CYANOPYRROLE SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR | WYETH (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | WYETH (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008075353-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | CNR2 41/4885CNR1 207/4885 |
| US-20090312414-A1 | Treatment Of Lower Urinary Tract Dysfunction With CB2-Receptor-Selective Agonists | CNR2, CNR1, GPR52 | CNR2 1/4885CNR1 2/4885 |
| US-20100204228-A1 | Aryl Sulfonamides Useful for Modulation of the Progesterone Receptor | FSHR, GNRHR, CYP19A1 | CNR2 128/4885CNR1 62/4885 |
| US-20080221201-A1 | 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake | PKD1, PKD2, SHBG | CNR2 559/4885CNR1 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.